Inovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb™) Platform in Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019
PLYMOUTH MEETING, Pa., Nov. 26 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that three recent published studies of its DNA-Encoded monoclonal antibody (dMAb™) technology showed impressive results in treating cardiovascular disease and in preventing infection from the Ebola virus and Lyme disease-causing bacteria in preclinical models. Leveraging several recent published positive preclinical [...]